Evidence map›Paper›PMID 26937129›Full record

ReviewWorld journal of gastroenterology2016

Advanced gastric cancer: Current treatment landscape and future perspectives.

Antonia Digklia, Anna Dorothea Wagner

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 357 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
357citing papers in PubMed, 3 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

357 citing papers in PubMed, 3 syntheses or guidelines pooled it, 577 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Integrating psychological and dietary care for patients with advanced gastric cancer undergoing chemotherapy: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Multi-omics exploration of hypoxia in gastric cancer.World journal of surgical oncology · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

297 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Antonia DigkliaAntonia Digklia, Anna Dorothea Wagner, Departement d'Oncologie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.
Anna Dorothea WagnerAntonia Digklia, Anna Dorothea Wagner, Departement d'Oncologie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.
University Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer currently ranks fourth in cancer-related mortality worldwide. In the western world, it is most often diagnosed at an advanced stage, after becoming metastatic at distant sites. Patients with advanced disease (locally advanced or metastatic) have a somber prognosis, with a median overall survival of 10-12 mo, and palliative chemotherapy is the mainstay of treatment. In recent years, novel approaches using inhibition of human epidermal growth factor receptor 2 (HER2) have demonstrated significant improvements in progression-free and overall survival, compared with chemotherapy alone, in first-line treatment of patients with overexpression of HER2. In addition, both second-line chemotherapy and treatment with the vascular endothelial growth factor receptor-inhibitor ramucirumab demonstrated significant benefits in terms of overall survival, compared with best supportive care, in randomized studies. Moreover, ramucirumab in combination with chemotherapy demonstrated further significant benefits in terms of progression-free and overall survival, compared with chemotherapy alone, in second-line treatment for patients with metastatic gastric cancer. A recently published molecular classification of gastric cancer is expected to improve patient stratification and selection for clinical trials and provide a roadmap for future drug development. Nevertheless, despite these developments the prognosis of patients with advanced gastric cancer remains poor. In this review we discuss current standards of care and outline major topics of drug development in gastric cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalDisease ProgressionDrug DiscoveryGenetic Predisposition to DiseaseHumansMolecular Diagnostic TechniquesMolecular Targeted TherapyNeoplasm StagingPalliative CarePhenotypePrecision MedicinePredictive Value of TestsRisk FactorsStomach NeoplasmsTime FactorsChemotherapyClinical trialsGastric cancerPerspectivesPhase IIITargeted therapy

Identifiers

PMID26937129
PMCPMC4768187
OpenAlexW2292909024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.